Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Hikma Pharmaceuticals PLC - London-based generic drugmaker - Receives preliminary approval from the US Federal Trade Commission for its planned acquisition of Custopharm Inc. Back in September, Hikma agreed to buy the California, US-based generic injectable products company for a total of up to $425 million.
Current stock price: 2,068.00 pence, down 0.6% on Wednesday
12-month change: down 13%
Copyright 2022 Alliance News Limited. All Rights Reserved.